Syvek® Ensures Effective Control of Bleeding

Syvek has been used on more than 3 million patients*. The product's efficacy is supported by documented case studies and peer-reviewed literature.

    Hemostatic Properties of Glucosamine-Based Materials
  • Different glucosamine polymers can have very different abilities to activate hemostatic systems. Microalgal-derived pGlcNAc was found to be the most effective polymeric material for accelerating fibrin polymerization.
  • Fischer T, Bode A, Demcheva M, et al. J Biomed Mater Res. 2007; 80A: 167-174.
    Non-Invasive Closure Devices: "Patches and Pads"
  • Syvek leads to rapid cessation of bleeding without leaving foreign material at the arterial puncture site or in the tissue tract, thereby reducing the potential for infection and for localized inflammatory tissue responses.
  • Hirsch JA, Reddy SA, Capasso WE,et al. Tech Vasc Interv Radiol. 2003;6:92-95.
    Early Sheath Removal with Angiomax and SyvekPatch
  • The Miami Heart cath lab completed a study using Angiomax® (bivalirudin) and the SyvekPatch®, testing early sheath removal. Results were excellent, and this protocol has become standard for some clinicians in the cath lab.
  • Drushal K, Pesek T. Cath Lab Digest. 2002; 10:16-18
    Control of Post-Dialysis Bleeding in Patients on Chronic Oral Anticoagulation Therapy
  • Extensive compression following dialysis can result in costly operational inefficiencies, expose patients and staff to bloodborne pathogens, and contribute to vascular access damage. Syvek was found to be a safe and effective method to rapidly control bleeding in hemodialysis patients versus manual compression with gauze or using clamps (n = 50). There were no cases of re-bleeding when using Syvek, and it significantly reduced compression time for hypertensive patients and patients taking concomitant anticoagulation.
  • Meyer K, Jenuleson C, Vital A, et al. Amer Soc Nephrol. 1999. Meeting Abstract.

Indications for Use: SyvekNT is intended for the promotion of rapid control of bleeding in patients following hemodialysis and in patients on anticoagulation therapy. SyvekNT is intended for use in the local management of bleeding wounds such as vascular access site, percutaneous catheters or tubes and surgical debridement.
Syvek Excel is intended for use following femoral vascular catheterization procedures to assist in obtaining and maintaining hemostasis.

Safety Information:
PRECAUTIONS: There are no known contraindications to the use of SyvekNT. Longer compression may be necessary for hypertensive or obese patients.
There are no known contraindications to the use of Syvek Excel. Longer compression may be necessary for hypertensive or obese patients.
CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician or other licensed practitioner

Manufactured by Marine Polymer Technologies, Inc., Danvers, MA 01923. For instructions for use or additional product information, please contact us.

* Data on file, based on total US sales

** Angiomax®(bivalirudin) is a registered trademark of The Medicines Company